Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder

NCT02897765 is registered in ClinicalTrials.gov with BioNTech US Inc. as lead sponsor.

NCT NCT02897765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02897765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Lead sponsor
BioNTech US Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2016
Completion date
May 31, 2020
Enrollment
34 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

bladder tumors, carcinoma, non-small-cell lung, lung cancer, malignant melanoma, melanoma, skin cancer, transitional cell carcinoma of the bladder, urinary bladder cancer